AIM2 and atherosclerosis: After AIM2 inflammasome activation, N-terminal domain of gasdermin D (GSDMD-NT) released from GSDMD via caspase-1 cleavage eventually results in cell pyroptosis and proinflammatory factor interleukin-1β (IL-1β) and interleukin-18 (IL-18) release, which is involved in the initiation and progression of atherosclerosis [4, 5].